home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc.

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milesto...
AIM - AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. Details for the pr...

AIM - AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial evaluating Ampligen® (rintatolim...

AIM - AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today ...
AIM - AIM ImmunoTech announces $2.65M financing priced at-market

2026-06-09 09:54:13 ET More on AIM ImmunoTech AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Fi...

AIM - AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM)  (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-m...

AIM - FDA Milestones Fueling Expansion

2026-06-08 10:00:57 ET Denver, Colorado ( www.247marketnews.com ) – The biotechnology sector delivered several notable developments . Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store Tango Therapeutics Delivers Eye-Catching Panc...
AIM - US Companies Moving the Markets, Morning edition
Mon, Jun 08, 2026 as of 10.00 am ET

A look at the top 10 most actives in the United States Dreamland Limited (TDIC) rose 78.5% to $0.3999 on volume of 217,052,822 shares Direxion Daily Semiconductor Bear 3X (SOXS) fell 16.5% to $5.7128 on volume of 214,794,989 shares Nocera Inc. (NCRA) rose 36.2% to $0.2181 on volume of 205,2...

AIM - AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen ® (rint...

AIM - AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript

2026-06-04 11:41:55 ET AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak June 4, 2026 9:00 AM EDT... Read the full article on Seeking Alpha For further details see: AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential R...
Next 10